Fluoroquinolones in the Management of Community-acquired Pneumonia in Primary Care

Brian Wispelwey; Katherine R Schafer


Expert Rev Anti Infect Ther. 2010;8(11):1259-1271. 

In This Article

Five-year View

Over the next few years, the development of rapid diagnostic tests for the differential diagnosis of CAP and the identification of resistant organisms will greatly enhance a clinician's ability to accurately diagnose CAP and rapidly initiate appropriate antibiotic therapy. Bacterial resistance will continue to be an issue, however, especially given the widespread use and frequent misuse/overuse of antibiotics in many settings, the limited number of antibiotics in a clinician's armamentarium and poor patient adherence. Noncompliance, which is often seen as an important reason for treatment failure, can be improved significantly as regimens are simplified (e.g., lower pill burden, shorter duration of therapy and improved tolerability), which is supported by current research. Also, as positive data showing the cost–effectiveness of fluoroquinolones in the outpatient setting continue to emerge, this may further encourage more appropriate use of fluoroquinolones (and antibiotics in general) to reduce the morbidity and mortality associated with bacteria-related CAP.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: